Proteostasis Therapeutics Receives FDA Fast Track Designation for PTI-428 in Patients With Cystic Fibrosis

CAMBRIDGE, MA--(Healthcare Sales & Marketing Network) - Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and protein processing diseases, today announced... Biopharmaceuticals, FDAProteostasis, DRT platform, Cystic Fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news